Compare OLOX & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLOX | CLDI |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.7M |
| IPO Year | 2011 | 2021 |
| Metric | OLOX | CLDI |
|---|---|---|
| Price | $0.80 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 40.3K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,952,578.00 | $45,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.09 |
| 52 Week High | $219.00 | $3.38 |
| Indicator | OLOX | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 26.99 |
| Support Level | $0.77 | $0.62 |
| Resistance Level | $1.29 | $1.29 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 26.49 | 14.15 |
Olenox Industries Inc provides modular structures made from code-engineered cargo shipping containers as permanent or temporary structures for residential housing, commercial structures, and industrial applications. Its segments are: Construction, Software-as-a-Service (SaaS), Oil and Gas, and Others. Construction segment generates maximum revenue and designs and constructs modular structures in its factory using recycled shipping containers; in the past, traditional wood and steel frames were also used. It markets its construction products to contractors, home builders, building owners, other resellers, large multinational corporations, government agencies, private developers, the U.S. Military, individual homeowners, and pop-up retailers across the continental United States and Canada.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.